EverHint – Dip Bounce V2 (Reclaim) – Top 15 Signals for Aug 19, 2026
Excerpt: 15 signals (from 39 total). Healthcare leads (14). price range $7-$1033. 1 with insider buying.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
Equity markets are trading in a constructive, low-volatility environment heading into August 19, 2026, with all three major indices posting modest but broad-based gains. The S&P 500, Nasdaq, and Dow Jones are moving in near-lockstep, suggesting a healthy risk-on tone without speculative excess concentrated in any single segment. This kind of measured, synchronized advance tends to support dip-bounce reclaim strategies, as the broader trend provides a reliable backstop for short-term pullbacks to resolve higher rather than cascade into deeper selling.
The VIX at 14.89 — down 6% on the session — is a particularly meaningful backdrop for dip_bounce_v2_reclaim signals. Low and falling volatility compresses intraday price ranges, which means reclaim setups need tighter confirmation thresholds to avoid false entries, but also tend to follow through more cleanly once a level is recaptured. The reduced fear premium in options pricing lowers the cost of hedging and encourages institutional participation on the buy side, which historically reinforces the type of mean-reversion dynamic these signals are designed to capture.
Healthcare leading as the top sector among today's 39 signals adds an interesting dimension. Defensive sector rotation into Healthcare during a broadly positive tape often signals that institutional money is selectively repositioning — maintaining market exposure while tilting toward relative safety. For dip-bounce setups, Healthcare names in this environment may offer a favorable combination of sector-level momentum and lower beta, reducing the risk of whipsaw while still providing meaningful upside on a successful reclaim.
📊 Signals (15 of 39 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | KO | The Coca-Cola Company | Consumer Defensive | $90.35 | 0.36 | — | $388.7B |
| 2 | ARGX | argenx SE | Healthcare | $1032.86 | 0.35 | — | $64.2B |
| 3 | MDLZ | Mondelez International... | Consumer Defensive | $64.16 | 0.32 | — | $81.9B |
| 4 | INCY | Incyte Corporation | Healthcare | $128.47 | 0.30 | — | $26.0B |
| 5 | RLI | RLI Corp. | Financial Services | $64.31 | 0.28 | — | $5.9B |
| 6 | BBIO | BridgeBio Pharma, Inc. | Healthcare | $83.95 | 0.28 | — | $16.4B |
| 7 | ECL | Ecolab Inc. | Basic Materials | $285.62 | 0.27 | — | $80.4B |
| 8 | AWK | American Water Works C... | Utilities | $138.71 | 0.26 | — | $27.6B |
| 9 | ASND | Ascendis Pharma A/S | Healthcare | $259.62 | 0.25 | Buy +$222,219 | $16.1B |
| 10 | ADUS | Addus HomeCare Corpora... | Healthcare | $120.02 | 0.24 | — | $2.2B |
| 11 | DNP | DNP Select Income Fund... | Financial Services | $10.97 | 0.23 | — | $4.1B |
| 12 | MRVI | Maravai LifeSciences H... | Healthcare | $7.22 | 0.21 | — | $2.0B |
| 13 | BG | Bunge Global S.A. | Consumer Defensive | $114.00 | 0.20 | — | $21.9B |
| 14 | UNIT | Uniti Group Inc. | Real Estate | $10.33 | 0.17 | — | $2.5B |
| 15 | UNP | Union Pacific Corporation | Industrials | $301.80 | 0.17 | — | $179.3B |
Field Notes
Sector concentration: Healthcare (14), Industrials (6), Consumer Defensive (4)
Insider buying (7d): ASND (Ascendis Pharma A/S, +$222,219)
Congressional activity (30d): MDLZ (Mondelez International, Inc., 1 trades, Bearish)
Data coverage: 2.6% insider (7d), 2.6% congressional (30d), 0.0% earnings, 15.4% news (7d)
Peer Analysis
UNP (Union Pacific Corporation): Leads 5 peers: HON ($221.73), NSC ($345.71), DE ($580.63), CNI ($127.64), CSX ($50.68)
BBIO (BridgeBio Pharma, Inc.): Leads 5 peers: RVMD ($214.66), IONS ($60.80), ASND ($259.62), SMMT ($13.11), ROIV ($37.40)
ASND (Ascendis Pharma A/S): Leads 5 peers: IONS ($60.80), BBIO ($83.95), RVMD ($214.66), ROIV ($37.40), SMMT ($13.11)
Congressional Activity
MDLZ (Mondelez International, Inc.) 🔴 Bearish
- 1 sale by 1 member
Recent Headlines
ARGX (argenx SE)
- argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
AWK (American Water Works Company, Inc.)
- West Virginia American Water Announces $512,000 Infrastructure Upgrade on Fayette Avenue
- West Virginia American Water Announces $512,000 Infrastructure Upgrade on Fayette Avenue
- American Water Charitable Foundation and California American Water Award $20,000 Workforce Development Grant to Resources for Independent Living
MDLZ (Mondelez International, Inc.)
- MDLZ Q2 Sales Beat and Higher 2026 Growth View Put Margins in Focus
- Is MDLZ Worth Buying as Growth Improves but Valuation Stays Rich?
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (14 signals) suggests sector-specific rotation. 1 signal with insider buying adds conviction.
Trading tips for this strategy:
- Entry timing: Consider entering on next-day weakness or at previous day's close level
- Position sizing: Start small (1-2% of portfolio per signal)
- Stop loss: Below today's low (tight stops for mean reversion)
- Take profit: 3-5% bounce target, or previous day's high
- Time stop: Exit if no bounce in 1-3 days
Risk warning: Mean reversion can fail in strong downtrends - check broader market context
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.